PATENT
Attorney Docket No.: CUTLER-06326





## **DECLARATION FOR PATENT APPLICATION**

As the below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name. I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled Sublingual Administration of Dihydroergotamine For The Treatment Of Migraine, the specification of which is attached hereto. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor: Neal R. Cutler	
Inventor's Signature: Pouloused Los Angeles Colifornia 90077	Date: 2/12/02
Residence: 10464 Sunset Boulevard, Los Angeles, California 90077	Citizenship: United States of America
Post Office Address: 10464 Sunset Boulevard, Los Angeles, California 90077	



## COPY OF PAPERS **ORIGINALLY FILED**

PATENT

Attorney Docket No.: CUTLER-06326

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Neal R. Cutler

Group No .: Examiner:

Scrial No.:

09/899,412

Filed: Entitled: 07/05/01 Sublingual Administration of Dihydroergotamine For The Treatment Of

Migraine

## POWER OF ATTORNEY BY ASSIGNEE

Assistant Commissioner for Patents Washington, D.C. 20231

Alamo Pharmaceuticals, LLC, as Assignee of record of the entire interest of the above-identified patent application, hereby appoints the members of the firm of MEDLEN & CARROLL, LLP, a firm composed of:

Virginia S. Medlen	(Reg. No. 32,050)	Maha A. Hamdan	(Reg. No. 43,655)
Peter G. Carroll	(Reg. No. 32,837)	J. Mitchell Jones	(Reg. No. 44,174)
Kamrin T. MacKnight	(Reg. No. 38,230)	David J. Wilson	(Reg. No. 45,225)
David A. Casimir	(Reg. No. 42,395)	Jason R. Bond	(Rcg. No. 45,439)
Jaen Andrews	(Reg. No. 35,051)	Thomas J. Bordner	(Reg. No. 47,436)
Tanya A. Arenson	(Reg. No. 47,391)	Mary Ann Brow	(Reg. No. 42,363)
Thomas C. Howerton	(Reg. No. 48,650)	Thomas W. Brown	(Rcg. No. 50,002)

as its attorneys with full power of substitution to prosecute this application and transact all business in the Patent and Trademark Office in comection therewith.

Please direct all future correspondence and telephone calls regarding this application to:

Peter G. Carroll

MEDLEN & CARROLL, LLP

101 Howard Street, Suite 350

San Francisco, California 94105

Telephone: 415/904-6500 Facsimile: 415/904-6510

I hereby certify that the Assignment document filed with the application or filed subsequent to the filing date of the application, has been reviewed and I hereby certify that, to the best of my knowledge and belief, title is with Alamo Pharmaceuticals, LLC.

Alamo Pharmaceuticals, LLC 8501 Wilshire Boulevard, Suite 318 Beverly-Hills, California 90211